Alnylam Pharmaceuticals, BioMarin Pharmaceutical Inc., and

Alnylam Pharmaceuticals, BioMarin Pharmaceutical Inc., and Cytonet
Set to Speak on Conducting Effective Orphan Drug Research at marcus
evans Conference 
Barbara Wuebbels, R.N., M.S., Oved Amitay, and Rod Monroy, Ph.D. Set
to Speak at the Premier marcus evans Life Cycle of Orphan Drug
Development & Commercialization Conference 
BOSTON, MA -- (Marketwire) -- 11/16/12 --  marcus evans, a world
leading provider of strategic conferences, is pleased to introduce
the Life Cycle of Orphan Drug Development & Commercialization
Conference, January 16-18, 2013 in Boston, Mass.  
The orphan drug and rare disease industry is one of the hottest
topics in modern day medicine. "A unique set of patients with rare
diseases and severe unmet medical needs exists; it is essential to
have people and companies dedicated to develop therapeutic agents to
improve the quality of life for these patients," said Rod Monroy,
Ph.D., Senior Director, North American Clinical Operations at
Cytonet. With blockbuster drugs coming off patent, there is a great
need for pharmaceutical companies to diversify their portfolios by
exploring niche markets. The increasing presence of high-profile
manufacturers in the orphan drug industry provides these companies
with this opportunity. 
Orphan drug development has several advantages including faster
clinical trials, better odds for approval with an 82% success rate,
attractive profitability, given the smaller patient populations, and
ongoing revenue growth. 
While the orphan drug market offers an attractive future for the
pharmaceutical industry, it is not without challenges, which include
clinical trial end points and lack of biomarkers and difficulty
identifying patients. "Finding key opinion leaders and funding the
clinical trial are two of the major challenges in orphan drug
development," said Barbara Wuebbels, Associate Director, Patient
Advocacy & Investigator Relations at BioMarin Pharmaceutical Inc. 
Growing regulatory issues and demands, a changing reimbursement
environment, and outdated distribution models add uncertainty and
increase the financial risks. "As we continue to drive scientific
innovation to the benefit of patients we need to work with other
stakeholders on evolving the commercial paradigms to ensure
sustainable long-term success," said 
Oved Amitay, Vice President and
Head of Commercial at Alnylam Pharmaceuticals. 
The Life Cycle of Orphan Drug Development & Commercialization
Conference will focus on the current landscape of rare disease and
orphan drug development, different forms of structural-based drug
designs, and specifically designed clinical trials. Through these
clinical trials, and by having connected to the right patients to
participate, will increase productivity and expedite orphan drug
approval and commercialization of the final product. 
For more information regarding this conference and to register,
please visit http://www.marcusevansch.com/LCOD2012_PR  
About marcus evans 
marcus evans conferences annually produce over 2,000 high quality
events designed to provide key strategic business information, best
practice and networking opportunities for senior industry
decision-makers. Our global reach is utilized to attract over 30,000
speakers annually; ensuring niche focused subject matter presented
directly by practitioners and a diversity of information to assist
our clients in adopting best practice in all business disciplines. 
Media Contact 
Robin Yegelwel
Marketing & PR Coordinator
marcus evans
robiny@marcusevansch.com 
 
 
Press spacebar to pause and continue. Press esc to stop.